References:
1. Simmons E.M., Himmelfarb J., Sezer M.T., Chertow G.M., Mehta R.L., Paganini E.P. et al. Plasma cytokine levels predict mortality in patients with acute renal failure. Kidney Int. 2004; 65(4): 1357-65.
2. Zhiznevskaya I.I., Khmelevskaya I.G., Razinkova N.S., Kalinina Z.N. Dynamics of immunological parameters in acute and chronic glomerulonephritis in children. Fundamental´nye issledovaniya. 2014; 4 (2): 269-73. (in Russian)
3. Zhang Z., Wang H., Zhang L., Crew R., Zhang N., Liu X. et al.. Serum Levels of Soluble ST2 and IL-10 Are Associated with Disease Severity in Patients with IgA Nephropathy. J. Immunol. Res. 2016; 2016:6540937.
4. Al-Eisa A.A., Al Rushood M., Al-Attiyah R.J. Urinary excretion of IL-1β, IL-6 and IL-8 cytokines during relapse and remission of idio-pathic nephrotic syndrome. J. Inflamm. Res. 2017; 10:1-5.
5. Beal A. L., Cerra F. B. Multiple organ failure syndrome in the 1990s. Systemic inflammatory response and organ dysfunction. JAMA. 1994; 271(3): 226-33.
6. Suzuki K., Nakaji S., Yamada M., Totsuka M., Sato K., Sugawara K. Systemic inflammatory response to exhaustive exercise. Cy-tokine kinetics. Exerc. Immunol. Rev. 2002; 8: 6-48.
7. Wada T., Furuichi K., Segawa-Takaeda C., Shimizu M., Sakai N., Takeda S.I. et al. MIP-1alpha and MCP-1 contribute to crescents and interstitial lesions in human crescentic glomerulonephritis. Kid-ney Int. 1999; 56(3): 995–1003.
8. Stangou M., Bantis C., Skoularopoulou M., Korelidou L., Kou-loukouriotou D., Scina M. et al. Th1, Th2 and Treg/T17 cytokines in two types of proliferative glomerulonephritis. Indian J. Nephrol. 2016; 26(3):159-66.
9. Sugama K., Suzuki K., Yoshitani K., Shiraishi K., Kometani T. Uri-nary excretion of cytokines versus their plasma levels after endur-ance exercise. Exerc. Immunol. Rev. 2013; 19: 29-48.
10. Kalavrizioti D., Gerolymos M., Rodi M., Kalliakmani P., Pro-vatopoulou S., Eleftheriadis T. et al. “T helper (Th)-cytokines in the urine of patients with primary glomerulonephritis treated with immunosuppressive drugs: can they predict outcome?” Cytokine. 2015; 76(2): 260–9.
11. Cho B.S., Yoon S.R., Jang J.Y., Pyun K.H., Lee C.E. Upregulation of interleukin-4 and CD23/Fc epsilon RII in minimal change neph-rotic syndrome. Pediatr. Nephrol. 1999; 13(3): 199–204.
12. Noronha I.L., Niemir Z., Stein H., Waldherr R. Cytokines and growth factors in renal disease. Nephrol. Dial. Transplant. 1995; 10(6): 775–86.
13. Pereira Wde F., Brito-Melo G.E., Guimarгes F.T., Carvalho T.G., Mateo E.C., Simхes e Silva A.C. The role of the immune system in idiopathic nephrotic syndrome: a review of clinical and experimen-tal studies. Inflamm. Res. 2014; 63(1): 1–12.
14. Shao X.S., Yang X.Q., Zhao X.D., Li Q., Xie Y.Y., Wang X.G. et al. The prevalence of Th17 cells and FOXP3 regulate T cells (Treg) children with primary nephrotic syndrome. Pediatr. Nephrol. 2009; 24(9): 1683–90.
15. Kanai T., Yamagata T., Momoi M.Y. Macrophage inflammatory protein-1beta and interleukin-8 associated with idiopathic steroid-sensitive nephrotic syndrome. Pediatr. Int. 2009; 51(4): 443–7.
16. Meng X.M., Nikolic-Paterson D.J., Lan H.Y. Inflammatory process-es in renal fibrosis. Nat. Rev. Nephrol. 2014; 10(9): 493–503.
17. Kurts C., Panzer U., Anders H.J., Rees A.J. The immune system and kidney disease: Basic concepts and clinical implications. Nat. Rev. Immunol. 2013; 13(10): 738–53.
18. Bai J., Wu L., Chen X., Wang L., Li Q., Zhang Y. et al. Suppressor of Cytokine Signaling-1/STAT1 Regulates Renal Inflammation in Mesangial Proliferative Glomerulonephritis Models. Front. Immu-nol. 2018; 9: 1982.
19. Lichtnekert J., Kulkarni O.P., Mulay S.R., Rupanagudi K.V., Ryu M., Allam R. et al. Anti-GBM glomerulonephritis involves IL-1 but is independent of NLRP3/ASC inflammasome-mediated activation of caspase-1. PLoS One. 2011; 6(10): e26778.
20. Pan Q., Wu J., Tao J., Chen Y., Li L., Deng Z. et al. Role of baso-phils in the pathogenesis of minimal change nephrotic syndrome: a literature review. Exp. Ther. Med. 2014; 8(4): 1027–31.
21. Zhang J., Patel M.B., Griffiths R., Mao A., Song Y.S., Karlovich N.S. et al. Tumor necrosis factor-α produced in the kidney contrib-utes to angiotensin II-dependent hypertension. Hypertension. 2014; 64(6): 1275-81.
22. Pedigo C.E., Ducasa G.M., Leclercq F., Sloan A., Mitrofanova A., Hashmi T. et al. Local TNF causes NFATc1-dependent cholesterol-mediated podocyte injury. J. Clin. Invest. 2016; 126(9): 3336-50.
23. VeldenJ.,PaustH.J.,HoxhaE.,TurnerJ.E.,SteinmetzO.M.,WolfG. et al. Renal IL-17 expression in human ANCA-associated glomerulo-nephritis. Am. J. Physiol. Renal Physiol. 2012; 302(12): 1663–73.
24. Zhou L., Lopes J.E., Chong M.M., Ivanov II., Min R., Victora G.D. et al. TGF-beta-induced Foxp3 inhibits T(H) 17 cell differentiation by an-tagonizing RORgammat function. Nature. 2008; 453(7192): 236–40.
25. Korn T., Reddy J., Gao W., Bettelli E., Awasthi A., Petersen T.R. et al. Myelin-specific regulatory T cells accumulate in the CNS but fail to control autoimmune inflammation. Nat. Med. 2007; 13(4): 423–31.
26. Shin J.I. Inverse relationship between soluble urokinase receptors and estimated glomerular filtration rate: a role for IL-2? Kidney Int. 2015; 87(5): 1074.
27. Shishido S., Satou H., Muramatsu M., Hamasaki Y., Ishikura K., Hataya H. et al. Combination of pulse methylprednisolone infu-sions with cyclosporine-based immunosuppression is safe and ef-fective to treat recurrent focal segmental glomerulosclerosis after pediatric kidney transplantation. Clin. Transplant. 2013; 27(2): 143–50.
28. Hua K. F., Yang S. M., Kao T. Y., Chang J. M., Chen H. L., Tsai Y. J. et al. Osthole mitigates progressive IgA nephropathy by inhibiting reactive oxygen species generation and NF-κB/NLRP3 pathway. PLoS One. 2013; 8(10): e77794.
29. Gao J., Wei L., Liu X., Wang L., Niu D., Jin T. et al. Association Between IFN-γ Gene Polymorphisms and IgA Nephropathy in a Chinese Han Population. Kidney Blood Press. Res. 2017; 42(1): 136-44.
30. Kim A.H., Chung J.J., Akilesh S., Koziell A., Jain S., Hodgin J.B. et al. B cell-derived IL-4 acts on podocytes to induce proteinuria and foot process effacement. JCI Insight. 2017; 2(21): e81836.
31. Lan H.Y., Nicolic-Paterson D.J., Zarama M., Vannice J.L., Atkins R.C. Suppression of experimental crescentic glomerulonephritis by the interleukin-1 receptor antagonist. Kidney Int. 1993; 43(2): 479–85.
32. Chen A., Sheu L.F., Chou W.Y., Tsai S.C., Chang D.M., Liang S.C. et al. Interleukin-1 receptor antagonist modulates the progression of a spontaneously occurring IgA nephropathy in mice. Am. J. Kidney Dis. 1997; 30(5): 693–702.
33. Yin Z., Bahtiyar G., Zhang N., Liu L., Zhu P., Robert M.E. et al. IL-10 regulates murine lupus. J. Immunol. 2002; 169(4): 2148–55.
34. 34.ZhangR.,LiQ.,ChuangP.Y.,LuG.,LiuR.,YangJ.etal.Regulation of pathogenicTh17 cell differentiation by IL-10 in the development of glomerulonephritis. Am. J. Pathol. 2013; 183(2): 402-12.
35. Ostmann A., Paust H.J., Panzer U., Wegscheid C., Kapffer S., Huber S. et al. Regulatory T cell-derived IL-10 ameliorates crescentic GN. J. Am. Soc. Nephrol. 2013; 24(6): 930-42.
36. Zhiznevskaya I.I., Khmelevskaya I.G. Features of cytokine profile in children with glomerulopathy. Kurskiy nauchno-prakticheskiy vestnik Chelovek i ego zdorov´e. 2013; 1: 62–6. (in Russian)